Who makes sapacitabine, Arm E?

sapacitabine, Arm E is developed by Cyclacel Pharmaceuticals, Inc..

What development phase is sapacitabine, Arm E in?

sapacitabine, Arm E is in Phase 2.

Last reviewed 2026-04-19 · How we verify

sapacitabine, Arm E

Cyclacel Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	sapacitabine, Arm E
Also known as	CYC682
Sponsor	Cyclacel Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

sapacitabine, Arm E CI brief — competitive landscape report
sapacitabine, Arm E updates RSS · CI watch RSS
Cyclacel Pharmaceuticals, Inc. portfolio CI